Isaac E. Ciechanover Sells 7,800 Shares of Atara Biotherapeutics Inc (ATRA) Stock

Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 7,800 shares of the stock in a transaction dated Thursday, January 10th. The shares were sold at an average price of $34.55, for a total value of $269,490.00. Following the completion of the sale, the chief executive officer now owns 733,285 shares of the company’s stock, valued at $25,334,996.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NASDAQ:ATRA opened at $35.01 on Friday. Atara Biotherapeutics Inc has a 52-week low of $22.15 and a 52-week high of $54.45. The stock has a market capitalization of $1.55 billion, a PE ratio of -8.75 and a beta of 2.47.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 6th. The biotechnology company reported ($1.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.13) by ($0.16). As a group, research analysts anticipate that Atara Biotherapeutics Inc will post -4.82 EPS for the current year.

Large investors have recently made changes to their positions in the company. Neuberger Berman Group LLC raised its stake in shares of Atara Biotherapeutics by 6.5% in the third quarter. Neuberger Berman Group LLC now owns 1,218,539 shares of the biotechnology company’s stock worth $50,386,000 after purchasing an additional 74,833 shares during the last quarter. SG Americas Securities LLC purchased a new position in shares of Atara Biotherapeutics in the third quarter worth about $108,000. Rhumbline Advisers raised its stake in shares of Atara Biotherapeutics by 16.9% in the second quarter. Rhumbline Advisers now owns 39,238 shares of the biotechnology company’s stock worth $1,442,000 after purchasing an additional 5,673 shares during the last quarter. United Services Automobile Association raised its stake in shares of Atara Biotherapeutics by 28.4% in the second quarter. United Services Automobile Association now owns 8,132 shares of the biotechnology company’s stock worth $299,000 after purchasing an additional 1,797 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its stake in shares of Atara Biotherapeutics by 35.6% in the third quarter. JPMorgan Chase & Co. now owns 1,202,912 shares of the biotechnology company’s stock worth $49,741,000 after purchasing an additional 315,921 shares during the last quarter.

A number of equities research analysts have commented on ATRA shares. BidaskClub cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Friday, October 12th. Cowen reiterated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, November 30th. Finally, Zacks Investment Research cut Atara Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Monday, December 31st. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. Atara Biotherapeutics has an average rating of “Hold” and an average price target of $47.80.

COPYRIGHT VIOLATION WARNING: “Isaac E. Ciechanover Sells 7,800 Shares of Atara Biotherapeutics Inc (ATRA) Stock” was originally posted by Markets Daily and is the property of of Markets Daily. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://www.themarketsdaily.com/2019/01/12/isaac-e-ciechanover-sells-7800-shares-of-atara-biotherapeutics-inc-atra-stock.html.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company is developing tabelecleucel, an advanced T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Further Reading: How to Invest in a Bull Market

Insider Buying and Selling by Quarter for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply